Financial Summary for the group
KSEK | 2023-04-01 | 2022-04-01 | 2023-01-01 | 2022-01-01 |
2023-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | |
Net turnover | 0 | 0 | 0 | 0 |
Profit/loss before tax | -5 910 | -12 711 | -11 887 | -29 389 |
Total assets | 41 399 | 65 926 | 41 399 | 65 926 |
Earnings per share before and after dilution (SEK) | -0,06 | -0,13 | -0,12 | -0,31 |
Cash and cash equivalents as per period end | 15 058 | 48 582 | 15 058 | 48 582 |
Equity ratio as per period end | 84,9% | 91,0% | 84,9% | 91,0% |
Significant events during the second quarter of 2023
Cyxone receives patent approval from the US for the salt forms of the compound rabeximodCyxone receives Intention to Grant from theEuropean Patent Office for the divisional patent of T20KCyxone appointsUrban Ottosson as new CFOCyxone engages Asperion as new strategical advisor
Significant events after the end of the period
Cyxone revised strategy for commercial alignment targeting valuable market opportunities
CEO Carl-Magnus Högerkorp comments
A new very industrially experienced board of directors took office in
A changing market provides positive prospects for rabeximod
The priority has initially been rabeximod, as the market is currently undergoing major changes due to patent losses that significantly affect the sales of the world's largest drug, Humira. A unique situation exists with the available phase II data on rabeximod, which has so far been evaluated in studies with 300 patients with good signs of efficacy and, not least, no signals of side effects that affect the possibilities of further development to treat patients.
During quarter four,
Cost-effective development process
I have been given a clear mission by the board to find ways to create value for both of these projects, while at the same time, at the board's request have started work on creating a more cost-effective operation with significantly lower costs. This is possible as, on the basis of the positive response we have received thus far, we conclude that key opinion-leading doctors in the US and
Please follow the company's development and receive information about our participation in investor meetings via Nasdaq First North Growth Market and on the company's website, www.cyxone.com.
Carl-Magnus Högerkorp
CEO
Upcoming financial reports
The report is enclosed in full here, and all reports will be available from these dates at www.cyxone.com
Submission of interim report
Malmö
The Board of Directors
Disclaimer
This is a translation of the original Swedish version of the interim report. In case of any discrepancy between this translation and the Swedish original, the latter shall prevail.
Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com
The information was submitted for publication, through the agency of the contact person set out above on 30th of
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.
About Cyxone
https://news.cision.com/cyxone/r/interim-report-1-january-to-30-june-2023,c3825899
https://mb.cision.com/Main/16882/3825899/2261436.pdf
(c) 2023 Cision. All rights reserved., source